Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.51 |
| ▸ | JAK3 | P52333 | 6/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.51 |
| ▸ | BRD4 | O60885 | 11/20 | 0.51 |
| ▸ | JAK1 | P23458 | 4/20 | 0.49 |
| ▸ | BUB1B | O60566 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | WEE1 | P30291 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265214 | 0.89 | BRD4 (0.49) | JAK2JAK3BRD4JAK1BUB1B | |
| SCHEMBL264498 | 0.89 | BRD4 (0.48) | JAK2JAK3BRD4JAK1BUB1B | |
| SCHEMBL264535 | 0.88 | KCNA5 (0.50) | JAK2JAK3BRD4JAK1BUB1B | |
| Hydrochloric Acid SCHEMBL263808 | 0.88 | BRD4 (0.49) | JAK2JAK3BRD4JAK1BUB1B | |
| SCHEMBL266184 | 0.86 | BRD4 (0.47) | JAK2JAK3BRD4JAK1BUB1B | |
| SCHEMBL265824 | 0.84 | BRD4 (0.46) | JAK2JAK3BRD4JAK1BUB1B | |
| SCHEMBL263688 | 0.84 | JAK2 (0.48) | JAK2JAK3PTK2BRD4JAK1 | |
| SCHEMBL265875 | 0.83 | BRD4 (0.63) | BRD4ALKAURKA | |
| SCHEMBL263544 | 0.79 | DHFR (0.44) | JAK2JAK3PTK2BRD4 | |
| SCHEMBL6313126 | 0.78 | HTR3A (0.52) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | JAK2 1/4885JAK3 3/4885PTK2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.